Startup profile · funding coverage
AKASA funding, valuation and investors
Generative AI platform automating healthcare revenue cycle operations.
Keep track of AKASA
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$120M · June 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$180M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · South San Francisco, California
Investors in latest funding
Other: Andreessen Horowitz , Coatue
Overview
AKASA uses generative AI to automate healthcare revenue cycle tasks — medical coding, prior authorization, claims, and denials — for hospitals and health systems.
Why AKASA is interesting
Unified automation for medical coding, prior auth, and claims — deployed across 650+ hospitals in customer base per company site.
Product & use cases
AKASA uses generative AI to automate healthcare revenue cycle tasks — medical coding, prior authorization, claims, and denials — for hospitals and health systems.
- Medical coding and claims automation for hospital revenue cycle teams
- Prior authorization workflow automation
- Denial prevention and revenue recovery for health systems
Key facts
- Series C (Jun 2024): $120M; a16z among investors (CB Insights / VCBacked)
- Series B (Mar 2021): $60M led by BOND with a16z and Costanoa (AKASA press)
- Series A (2019): led by a16z Bio + Health
- Deployed across 650+ hospitals and 6,500 outpatient facilities per company reporting
Funding history (newest first)
Investors in our directory
Funds linked from AKASA's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Hospital revenue cycle remains labor-intensive for coding, prior auth, and denials. AKASA's GenAI platform with expert-in-the-loop targets health systems representing $120B+ in net patient revenue. Competes with AI-native RCM startups and legacy vendors like Waystar; moat depends on EHR integration depth and coding accuracy on clinician gold sets.
-
Thoughtful AI direct
AI RCM automation competitor.
-
Olive AI adjacent
Prior RCM automation entrant (wind-down); AKASA focuses on unified GenAI platform.
-
Epic revenue cycle modules incumbent
EHR-native RCM; AKASA integrates within existing EHR workflows.
-
Waystar incumbent
Legacy RCM software; less AI-native than AKASA's GenAI approach.
Notable stories
- Series A (2019): led by a16z Bio + Health (a16z announcement)
- Series B (2021): $60M led by BOND with a16z and Costanoa participation (company press)
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover AKASA's financing or category context.
FAQs about AKASA
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.